Table 1.

AKS-452 Phase II characteristics of subjects at baseline.

Characteristic	Cohort 1 (1 × 90 ug)	Cohort 2 (2 × 45 ug)	Total
No. of Subjects	26	26	52
Sex -N (%)
Male	16	15	31 (59.6%)
Female	10	11	21 (40.4%)
Age - yr
Mean	43.3	39.7	41.5
Range	18–72	20–67	18–72
Race/Ethnicity - N (%)
Caucasian	26	24	50 (96.2%)
Black	0	1	1(1.9%)
Other	0	1	1 (1.9%)
Body Mass Index [Median (range)]	24.69 (19.66–29.13)	24.71 (19.31–29.99)	24.70 (19.31 – 29.99)
SARS-Cov-2 seronegative - N (%)	26	26	52 (100%)
Congenital abnormalities - N (%)
Cardiac abnormalities	1	0	1 (1.9%)
Non-cardiac abnormalities	0	0	0
No abnormalities	25	26	51 (98.1%)
Charlson Comorbidity Index (CCI) - N (%)
0	26	24	50 (96.2%)
1	0	2	2 (3.8%)
Use of medication in month prior to screening - N (%)	11	10	21 (40.4%)
Antibiotics/antiviral therapy	1	0	1 (1.9%)
Statins	1	1	2 (3.8%)
Hormone treatment	0	1	1 (1.9%)
Antihypertensive drugs	0	2	2 (3.8%)
Benzodiazepines	0	1	1 (1.9%)
Opiates	0	1	1 (1.9%)
Other	9	6	15 (28.8%)